NAFLD, MAFLD and obesity: brothers in arms?
Nature Reviews Gastroenterology & Hepatology, Published online: 05 December 2022; doi:10.1038/s41575-022-00717-42022 was a proficuous year in both the nonalcoholic fatty liver disease (NAFLD) and obesity fields. Pharmacological treatment for obesity and NAFLD is moving forward, with the possibility of replacing bariatric surgery, artificial intelligence might help us access the histological effects of new drugs, and there were advances in personalized hepatocellular carcinoma screening in patients with NAFLD.
Source: Nature Reviews Gastroenterology and Hepatology - Category: Gastroenterology Authors: Mariana Verdelho Machado Helena Cortez-Pinto Source Type: research
More News: Bariatric Surgery | Cancer & Oncology | Carcinoma | Eating Disorders & Weight Management | Fatty Liver Disease (FLD) | Gastroenterology | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Liver Transplant | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology